{"id":"https://openalex.org/W3097598574","doi":"https://doi.org/10.1182/blood-2020-137438","title":"Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)","display_name":"Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097598574","doi":"https://doi.org/10.1182/blood-2020-137438","mag":"3097598574"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-137438","doi":"https://doi.org/10.1182/blood-2020-137438","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137438","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000917771","display_name":"Michael U. Callaghan","orcid":"https://orcid.org/0000-0001-8742-0275","observed_orcids":["https://orcid.org/0000-0001-8742-0275"]},"institutions":[{"id":"https://openalex.org/I4210130818","display_name":"Children's Hospital of Michigan","ror":"https://ror.org/0429x9p85","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800326109","https://openalex.org/I4210130818"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael U. Callaghan","raw_affiliation_strings":["Children's Hospital of Michigan, Detroit, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Children's Hospital of Michigan, Detroit, MI","institution_ids":["https://openalex.org/I4210130818"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017113740","display_name":"Claude N\u00e9grier","orcid":"https://orcid.org/0000-0002-2905-055X","observed_orcids":["https://orcid.org/0000-0002-2905-055X","https://orcid.org/0000-0003-3569-0366"]},"institutions":[{"id":"https://openalex.org/I4210123600","display_name":"H\u00f4pital Edouard Herriot","ror":"https://ror.org/02qt1p572","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100596","https://openalex.org/I4210123600"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Claude N\u00e9grier","raw_affiliation_strings":["Edouard Herriot University Hospital, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Edouard Herriot University Hospital, Lyon, France","institution_ids":["https://openalex.org/I4210123600"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020690225","display_name":"Ido Paz\u2010Priel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ido Paz-Priel","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064981533","display_name":"Tiffany Y. Chang","orcid":"https://orcid.org/0009-0005-0699-8507","observed_orcids":["https://orcid.org/0009-0005-0699-8507"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tiffany Chang","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031572193","display_name":"Sammy Chebon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Sammy Chebon","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064882373","display_name":"Michaela Lehle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Michaela Lehle","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087552786","display_name":"Johnny Ndoni Mahlangu","orcid":"https://orcid.org/0000-0001-5781-7669","observed_orcids":["https://orcid.org/0000-0001-5781-7669"]},"institutions":[{"id":"https://openalex.org/I192619145","display_name":"University of the Witwatersrand","ror":"https://ror.org/03rp50x72","country_code":"ZA","type":"education","lineage":["https://openalex.org/I192619145"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Johnny Mahlangu","raw_affiliation_strings":["University of the Witwatersrand and NHLS, Johannesburg, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of the Witwatersrand and NHLS, Johannesburg, South Africa","institution_ids":["https://openalex.org/I192619145"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004338432","display_name":"Guy A. Young","orcid":"https://orcid.org/0000-0001-6013-1254","observed_orcids":["https://orcid.org/0000-0001-6013-1254"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1336910626","display_name":"Children's Hospital Los Angeles","ror":"https://ror.org/00412ts95","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336910626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guy Young","raw_affiliation_strings":["University of Southern California Keck School of Medicine, Children's Hospital Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Southern California Keck School of Medicine, Children's Hospital Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1336910626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086373140","display_name":"Rebecca Kruse\u2010Jarres","orcid":"https://orcid.org/0000-0001-6547-5240","observed_orcids":["https://orcid.org/0000-0001-6547-5240"]},"institutions":[{"id":"https://openalex.org/I2799735646","display_name":"Bloodworks Northwest","ror":"https://ror.org/00ek9j693","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I2799735646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Kruse-Jarres","raw_affiliation_strings":["BloodWorks NorthWest, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BloodWorks NorthWest, Seattle, WA","institution_ids":["https://openalex.org/I2799735646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033399787","display_name":"Maria Elisa Mancuso","orcid":"https://orcid.org/0000-0002-7113-4028","observed_orcids":["https://orcid.org/0000-0002-7113-4028"]},"institutions":[{"id":"https://openalex.org/I2803066834","display_name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","ror":"https://ror.org/016zn0y21","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I189158943","https://openalex.org/I2803066834","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Maria Elisa Mancuso","raw_affiliation_strings":["Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy","institution_ids":["https://openalex.org/I2803066834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015180940","display_name":"Markus Niggli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Markus Niggli","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060178320","display_name":"Peter Kuebler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Kuebler","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061091111","display_name":"Nives Selak Bienz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Nives Selak Bienz","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017307924","display_name":"Midori Shima","orcid":"https://orcid.org/0000-0002-5922-7061","observed_orcids":["https://orcid.org/0000-0002-5922-7061"]},"institutions":[{"id":"https://openalex.org/I4210113433","display_name":"Nara Medical University Hospital","ror":"https://ror.org/01wvy7k28","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210113433"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Midori Shima","raw_affiliation_strings":["Nara Medical University Hospital, Kashihara, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nara Medical University Hospital, Kashihara, Japan","institution_ids":["https://openalex.org/I4210113433"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050723834","display_name":"V\u00edctor Jim\u00e9nez\u2010Yuste","orcid":"https://orcid.org/0000-0003-3937-3499","observed_orcids":["https://orcid.org/0000-0003-3937-3499"]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Victor Jimenez-Yuste","raw_affiliation_strings":["Hospital Universitario La Paz, Autonoma University, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario La Paz, Autonoma University, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020001100","display_name":"Christophe Schmitt","orcid":"https://orcid.org/0000-0001-8001-5584","observed_orcids":["https://orcid.org/0000-0001-8001-5584"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Christophe Schmitt","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086435750","display_name":"Elina Asikanius","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Elina Asikanius","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110579558","display_name":"Gallia G. Levy","orcid":"https://orcid.org/0009-0008-2051-2819","observed_orcids":["https://orcid.org/0009-0008-2051-2819"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gallia Levy","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020488137","display_name":"Steven W. Pipe","orcid":"https://orcid.org/0000-0003-2558-2089","observed_orcids":["https://orcid.org/0000-0003-2558-2089"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven W. Pipe","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079861916","display_name":"Johannes Oldenburg","orcid":"https://orcid.org/0000-0002-1585-4100","observed_orcids":["https://orcid.org/0000-0002-1585-4100","https://orcid.org/0000-0003-3038-2145"]},"institutions":[{"id":"https://openalex.org/I135140700","display_name":"University of Bonn","ror":"https://ror.org/041nas322","country_code":"DE","type":"education","lineage":["https://openalex.org/I135140700"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Johannes Oldenburg","raw_affiliation_strings":["University of Bonn, Bonn, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Bonn, Bonn, Germany","institution_ids":["https://openalex.org/I135140700"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.3333,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.60305607,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":95},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"3","last_page":"5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/emicizumab","display_name":"emicizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hemophilia-a","display_name":"hemophilia A","score":0.9860000014305115},{"id":"https://openalex.org/keywords/factor-viii-inhibitors","display_name":"factor VIII inhibitors","score":0.9779999852180481},{"id":"https://openalex.org/keywords/prophylaxis","display_name":"prophylaxis","score":0.8069999814033508},{"id":"https://openalex.org/keywords/annualized-bleed-rate","display_name":"annualized bleed rate","score":0.8450000286102295},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.5979999899864197},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7919999957084656},{"id":"https://openalex.org/keywords/bleeding-events","display_name":"bleeding events","score":0.5},{"id":"https://openalex.org/keywords/coagulation-factor-consumption","display_name":"coagulation factor consumption","score":0.6919999718666077},{"id":"https://openalex.org/keywords/pediatric-and-adult-patients","display_name":"pediatric and adult patients","score":0.5920000076293945},{"id":"https://openalex.org/keywords/pooled-analysis","display_name":"pooled analysis","score":0.4320000112056732},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.6940000057220459},{"id":"https://openalex.org/keywords/factor-ix","display_name":"factor IX","score":0.3330000042915344},{"id":"https://openalex.org/keywords/factor-viia","display_name":"factor VIIa","score":0.5360000133514404},{"id":"https://openalex.org/keywords/factor-xia","display_name":"factor XIa","score":0.328000009059906},{"id":"https://openalex.org/keywords/factor-xiia","display_name":"factor XIIa","score":0.5929999947547913},{"id":"https://openalex.org/keywords/factor-xiiia","display_name":"factor XIIIa","score":0.49900001287460327}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6537512540817261},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5207045674324036},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4294856786727905},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3641526401042938},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34318220615386963}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-137438","doi":"https://doi.org/10.1182/blood-2020-137438","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137438","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3115183047","https://openalex.org/W4392353654","https://openalex.org/W4327933168","https://openalex.org/W3015702201","https://openalex.org/W2936143155","https://openalex.org/W7223477346","https://openalex.org/W4407461140","https://openalex.org/W3213505659","https://openalex.org/W3097601655","https://openalex.org/W4245065482"],"abstract_inverted_index":{"Introduction:":[0],"Emicizumab-a":[1],"subcutaneously":[2],"administered,":[3],"bispecific,":[4],"humanized,":[5],"monoclonal":[6],"antibody-promotes":[7],"effective":[8],"hemostasis":[9],"in":[10,44,119,211,226,432,527,551,572,591,777,892,925,936,942,956,1182,1298,1310],"people":[11],"with":[12,180,370,415,539,547,608,613,628,646],"hemophilia":[13],"A":[14],"(PwHA).":[15],"The":[16,74,241,265,275,303,411,543,638],"primary":[17],"efficacy":[18,68,149,228,307,320],"and":[19,57,69,78,133,150,182,186,202,216,221,365,388,401,447,467,515,532,555,560,575,603,632,643,657,912,973,1012,1041,1056,1154,1159],"safety":[20,70,242,660],"of":[21,37,71,127,147,178,190,198,204,233,251,277,298,306,316,322,336,382,390,413,438,534,545,577,584,593,606,626,640,676,690,709,725,744,755,768,787,799,813,828,909,985,987,995,1146,1207],"emicizumab":[22,86,107,148,252,259,586],"were":[23,141,279,366,537,557,570],"reported":[24],"previously,":[25],"but":[26,260,524],"long-term":[27,655],"data":[28,32,507],"are":[29,62,117,224],"limited.":[30],"Here,":[31],"from":[33,138,419],"a":[34,231,937],"wide":[35],"age-range":[36],"PwHA":[38,80,210,246,254,592],"with/without":[39,81,596],"factor":[40,192],"(F)VIII":[41],"inhibitors":[42],"enrolled":[43,76],"the":[45,66,131,227,290,337,348,397,475,564,604,618,621,624,943,1311],"Phase":[46],"III":[47],"HAVEN":[48,51,54,58,139,212,528],"1":[49,509,525],"(NCT02622321),":[50],"2":[52,94,533],"(NCT02795767),":[53],"3":[55,91,215,511,582],"(NCT02847637),":[56],"4":[59,100,217,333,516,535],"(NCT03020160)":[60],"studies":[61,75],"pooled":[63,142],"to":[64,105,111,257,294,368,422,425,472,601,665,1223],"establish":[65],"durable":[67],"emicizumab.":[72],"Methods:":[73],"pediatric":[77],"adult":[79],"FVIII":[82,287,439,597],"inhibitors.":[83,288,598],"Participants":[84,122],"received":[85,248,898],"prophylaxis":[87],"1.5":[88],"mg/kg":[89,92,98],"weekly,":[90],"every":[93,99],"weeks,":[95],"or":[96,282,678,692,711,727,746,757,770,789,801,815,830,939,997,1148,1209],"6":[97],"weeks.":[101],"All":[102,530,896],"participants":[103,179,278,299,317,326,383,391,414,469,546,607,627],"assigned":[104,110],"receive":[106,258],"(including":[108],"those":[109],"control":[112],"arms":[113],"who":[114,247],"later":[115],"switched)":[116],"included":[118,225],"this":[120,902],"analysis.":[121],"and/or":[123],"caregivers":[124],"recorded":[125],"outcomes":[126],"bleeding":[128],"events":[129,200,518],"via":[130,169],"Bleed":[132],"Medication":[134],"Questionnaire":[135],"(BMQ).":[136],"Data":[137],"1-4":[140],"for":[143,173,230,623,901,1152],"an":[144,319,673,687,706,722,741,752,765,784,796,810,825,992,1143,1204],"aggregate":[145],"analysis":[146,229],"safety.":[151],"Efficacy":[152],"endpoints":[153,195],"include":[154,196],"calculated":[155],"mean":[156],"annualized":[157,187],"bleed":[158,351,360,589],"rates":[159,590],"(ABRs;":[160],"discrete,":[161],"consecutive":[162,615],"24-week":[163,372,458,616],"treatment":[164,373,435,459,648],"intervals),":[165],"model-based":[166,349],"ABRs":[167,361,599],"(calculated":[168],"negative":[170],"binomial":[171],"regression":[172],"full":[174],"study":[175,295,329,423],"period),":[176],"percentage":[177,544],"zero":[181,385,404,609,629],"1-3":[183,393],"treated":[184,350,359,386,394,405,610],"bleeds,":[185,387],"cumulative":[188],"dose":[189,250],"coagulation":[191],"(ACD).":[193],"Safety":[194],"incidence":[197],"adverse":[199],"(AEs)":[201],"AEs":[203,473],"special":[205],"interest.":[206],"Results:":[207],"Overall,":[208],"400":[209],"1,":[213],"2,":[214],"(n=113,":[218],"88,":[219],"151,":[220],"48,":[222],"respectively)":[223],"total":[232],"970.3":[234],"patient":[235],"years":[236,583],"(cutoff:":[237],"15":[238],"May":[239],"2020).":[240],"population":[243],"comprises":[244],"399":[245],"\u22651":[249,548],"(1":[253],"was":[255,270,309,340,353,462,620],"randomized":[256],"did":[261],"not":[262],"start":[263],"treatment).":[264],"median":[266,304],"age":[267],"at":[268,427],"baseline":[269],"28.5":[271],"(range":[272],"1-77)":[273],"years.":[274],"majority":[276],"White":[280],"(66.8%)":[281],"Asian":[283],"(18.8%);":[284],"52.3%":[285],"had":[286,300,318,384,392,403],"In":[289],"24":[291,945],"weeks":[292],"prior":[293,421],"entry,":[296],"60.9%":[297,420],"target":[301,416,635],"joints.":[302],"duration":[305],"period":[308,321,339],"120.4":[310],"(interquartile":[311],"range":[312],"89.0-164.4)":[313],"weeks;":[314,324],"85.0%":[315],"\u226574":[323],"11":[325],"(2.8%)":[327],"discontinued":[328,470],"treatment.":[330],"Across":[331,345],"all":[332,346,433,523,594,634],"studies,":[334,347],"90.9-94.8%":[335],"observation":[338],"covered":[341],"by":[342,905,914],"completed":[343],"BMQs.":[344],"ABR":[352],"1.4":[354],"(95%":[355],"confidence":[356],"interval":[357],"1.1-1.7);":[358],"remained":[362],"low":[363,588],"throughout,":[364],"seen":[367],"decrease":[369,602],"successive":[371,647],"intervals":[374],"(Table":[375,440,465],"1).":[376,410],"During":[377,396],"Weeks":[378,428,552],"121-144":[379],"(n=170),":[380],"82.4%":[381],"15.3%":[389],"bleeds.":[395],"same":[398,565,622],"period,":[399],"91.8%":[400],"90.0%":[402],"spontaneous/joint":[406],"bleeds":[407,611,631],"respectively":[408],"(Figure":[409],"proportion":[412,605,625],"joints":[417,636],"reduced":[418],"entry":[424],"4.6%":[426],"1-24,":[429,553],"then":[430],"<1.5%":[431],"subsequent":[434],"intervals.":[436,649],"ACD":[437],"2),":[441],"activated":[442,448],"prothrombin":[443],"complex":[444],"concentrate":[445],"(aPCC)":[446],"recombinant":[449],"FVII":[450],"(rFVIIa,":[451],"Table":[452],"3)":[453],"generally":[454],"decreased":[455,645],"across":[456],"each":[457,614],"interval.":[460],"Emicizumab":[461,650],"well":[463,652],"tolerated":[464,653],"4),":[466],"no":[468,658],"due":[471],"beyond":[474],"five":[476],"previously":[477],"described":[478],"(Oldenburg":[479],"et":[480,488,493,501],"al.":[481,489,494,502],"N":[482,495],"Engl":[483,496],"J":[484,497],"Med":[485,498],"2017;":[486],"Young":[487],"Blood":[490,805],"2019;":[491],"Mahlangu":[492],"2018;":[499],"Pipe":[500],"Lancet":[503],"Haem":[504],"2019).":[505],"At":[506],"cut,":[508],"fatality,":[510],"thrombotic":[512],"microangiopathies":[513],"(TMAs),":[514],"thromboembolic":[517],"(TEs)":[519],"have":[520,662],"been":[521,663],"reported;":[522],"occurred":[526],"1.":[529],"TMAs":[531],"TEs":[536],"associated":[538],"concomitant":[540],"aPCC":[541],"use.":[542],"drug-related":[549],"AE":[550],"25-48":[554],"49-72":[556],"28.8%,":[558],"6.8%,":[559],"3.0%":[561],"respectively;":[562],"over":[563,654],"intervals,":[566],"injection":[567],"site":[568],"reactions":[569],"observed":[571],"23.3%,":[573],"4.8%,":[574],"2.5%":[576],"participants.":[578],"Conclusions:":[579],"With":[580],"nearly":[581],"follow-up,":[585,656],"maintained":[587],"ages,":[595],"continued":[600],"increased":[612],"period;":[617],"trend":[619],"joint":[630],"almost":[633],"resolved.":[637],"ACDs":[639],"FVIII,":[641],"aPCC,":[642],"rFVIIa":[644],"remains":[651],"new":[659],"concerns":[661],"identified":[664],"date.":[666],"Disclosures":[667],"Callaghan:":[668],"Bayer:":[669,1269],"Honoraria,":[670,684,703,719,738,762,781,793,807,822],"Membership":[671,685,704,720,739,750,763,782,794,808,823,990,1141,1202],"on":[672,686,705,721,740,751,764,783,795,809,824,991,1142,1203],"entity's":[674,688,707,723,742,753,766,785,797,811,826,993,1144,1205],"Board":[675,689,708,724,743,754,767,786,798,812,827,994,1145,1206],"Directors":[677,691,710,726,745,756,769,788,800,814,829,996,1147,1208],"advisory":[679,693,712,728,747,758,771,790,802,816,831,998,1149,1210],"committees,":[680,694,713,729,817,832],"Speakers":[681,700,716,819,838,842,1014,1092,1123,1219],"Bureau;":[682,701,717,820,839,843,1015,1124,1220],"Biomarin:":[683],"Other:":[695,730,833,859,895],"Site":[696,731,834],"Investigator/sub-I":[697,732,835],"Clinical":[698,733,836,1158],"Trial,":[699,734,837],"Shire:":[702],"Research":[714,735,851,979,1031,1043,1075,1160,1250,1287],"Funding,":[715],"Pfizer:":[718,1279,1286],"Funding;":[736,852,1044,1076,1251],"Grifols:":[737],"committees;":[748,759,772,791,803,999,1150,1211],"Bioverativ:":[749],"Hema":[760],"Biologics:":[761],"Alnylum:":[773],"Current":[774,883,889,920,922,932,951,953,1167,1173,1177,1179,1190,1293,1295,1302],"equity":[775,890,923,935,954,1180,1296],"holder":[776,891,924,955,1181,1297],"publicly-traded":[778,893,926,940,1183,1299],"company;":[779],"Spark:":[780,879,1074],"Octapharma:":[792],"Global":[804],"Therapeutics:":[806],"Other,":[818,841],"Roche/Genentech:":[821],"NovoNordisk:":[840],"Sancillio:":[844],"Other.":[845],"N\u00e9grier:CSL":[846],"Behring,":[847,865,960,1001,1018,1035,1064,1071,1082,1096,1113,1127,1244,1268],"Octapharma,":[848,870,1104,1120,1135,1266],"Shire/Takeda,":[849,877],"Sobi:":[850,858,1122,1140],"CSL,":[853],"F.":[854,872,885,915,967,1006,1026,1088,1100,1116,1131,1195,1238,1271],"Hoffmann-La":[855,873,886,916,929,948,968,1007,1027,1089,1101,1117,1132,1170,1187,1196,1239,1290],"Roche":[856,874,887,930,949,969,1008,1028,1090,1102,1118,1133,1171,1188,1197,1240,1258,1273,1291,1306],"Ltd,":[857,875,970,1009,1029,1103,1119,1134,1198,1241,1259,1274],"Travel":[860],"support;":[861],"Bayer,":[862,1111,1125,1200,1217],"Biomarin,":[863,1077],"CSL":[864,1000,1017,1034,1063,1070,1081,1095,1112,1126,1243,1267],"Freeline,":[866,1036,1046],"LFB,":[867],"Novo":[868,965,1004,1021,1050,1097,1114,1128,1247,1260,1275,1282],"Nordisk,":[869,966,1005,1022,1051,1098,1115,1129,1248,1261,1276,1283],"Pfizer,":[871,1024,1099,1130,1264],"Sanofi,":[876,971,1010,1025,1216,1242],"Sobi,":[878,1107,1263,1278,1285],"Consultancy.":[880,1255],"Paz-Priel:Genentech,":[881],"Inc:":[882],"Employment;":[884,1303],"Ltd:":[888,931,950,1091,1172,1189,1292,1307],"company,":[894],"authors":[897],"editorial":[899],"support":[900],"abstract,":[903],"provided":[904],"Scott":[906],"Battle,":[907],"PhD,":[908],"Health":[910,982],"Interactions":[911],"funded":[913],"Roche..":[917],"Chang:Genentech,":[918],"Inc.:":[919,1068,1086,1176],"Employment,":[921,933,952,1178,1294],"company.":[927,958,1184,1300],"Chebon:F.":[928],"Divested":[934],"private":[938,957],"company":[941],"past":[944,1312],"months.":[946],"Lehle:F.":[947],"Mahlangu:CSL":[959],"Catalyst":[961,1002],"Biosciences,":[962,1003],"Freeline":[963,1019],"Therapeutics,":[964,1020,1066,1084],"Spark":[972,1011],"Takeda:":[974,1013,1042],"Consultancy;":[975,1038,1069,1110,1280],"South":[976,988],"Africa":[977],"Medical":[978],"Council,":[980],"Wits":[981],"Consortium,":[983],"Colleges":[984],"Medicine":[986],"Africa:":[989],"BioMarin,":[1016,1045,1199],"Novartis,":[1023],"uniQure:":[1030],"Funding.":[1032,1288],"Young:Bayer,":[1033],"UniQure:":[1037,1057],"Genentech/Roche,":[1039,1047],"Grifols,":[1040,1048,1106,1121,1137,1265,1281],"Kedrion,":[1049,1105,1136,1139],"Sanofi":[1052],"Genzyme,":[1053],"Spark,":[1054],"Takeda,":[1055,1262,1277,1284],"Honoraria.":[1058],"Kruse-Jarres:Biomarin,":[1059],"Chugai":[1060,1078,1212,1230,1234,1252],"Pharmaceutical":[1061,1079,1193,1213,1231,1235,1253],"Co.,":[1062,1080,1194],"CRISPR":[1065,1083],"Genentech,":[1067,1072,1085],"Inc.,":[1073],"Honoraria;":[1087,1233,1270],"Bureau.":[1093],"Mancuso:Bayer,":[1094],"PedNet":[1108],"Foundation:":[1109],"Catalyst,":[1138],"Center":[1151,1161],"Thrombosis":[1153],"Hemorrhagic":[1155],"Diseases,":[1156],"Humanitas":[1157],"-":[1162],"IRCCS,":[1163],"Rozzano,":[1164],"Milan,":[1165],"Italy:":[1166],"Employment.":[1168,1174,1191],"Niggli:F":[1169],"Kuebler:Genentech,":[1175],"Selak":[1185],"Bienz:F.":[1186],"Shima:Chugai":[1192],"Sanofi:":[1201],"Co.":[1214,1236],",":[1215,1237],"Sysmex:":[1218],"Patents":[1221,1227],"related":[1222],"anti-FIXa/FX":[1224],"bispecific":[1225],"antibodies:":[1226],"&":[1228],"Royalties;":[1229],"Co.:":[1232,1254],"KM":[1245],"Biologics,":[1246],"Shire/Takeda:":[1249],"Jimenez-Yuste:F.":[1256],"Hoffman-La":[1257,1272,1305],"Schmitt:F.":[1289],"Asikanius:Fimea:":[1301],"F":[1304],"Ended":[1308],"employment":[1309]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}